On October 18, 2017 Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, reported that it will present data on lead checkpoint inhibitor CPI-444 from its ongoing Phase 1/1b study in an oral session at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 32ND Annual Meeting, which is taking place November 8-12 in National Harbor, Maryland. Following are the details for the oral presentation (Press release, Corvus Pharmaceuticals, OCT 18, 2017, View Source;p=RssLanding&cat=news&id=2309621 [SID1234521012]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Know more, wherever you are:
Latest on SITC (Free SITC Whitepaper) through 1stOncology, book your free 1stOncology demo here.
ORAL PRESENTATION
TITLE: Clinical Activity of Adenosine A2a Receptor (A2aR) Inhibitor CPI-444 is Associated with Tumor Expression of Adenosine Pathway Genes and Tumor Immune Modulation
PRESENTER: Jason J. Luke, M.D., FACP, Assistant Professor of Medicine, University of Chicago Medicine
SESSION: Clinical Trials: Novel Combinations
PRESENTATION DATE AND TIME: November 11, 2017, 5:45 – 6:00 p.m. EST